Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Desperate patient gets experimental stem cells for rare nerve disease

NCT ID NCT04825613

Disease control Sponsor: Hope Biosciences Research Foundation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended) This study
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study provides an experimental stem cell treatment (HB-adMSCs) to an 83-year-old man with Primary Lateral Sclerosis, a rare nerve disease that causes progressive muscle weakness. The patient's own banked stem cells are used, aiming to slow the disease. This is a single-patient expanded access program, not a full clinical trial, so results are very limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HB-adMSCs (adipose-derived mesenchymal stem cells)
What this could lead to
If it works, this could point toward a treatment that slows progression of Primary Lateral Sclerosis.
What could go wrong
This is a single-patient expanded access study, not a formal trial, so results may not apply to others. The treatment is still experimental with unknown risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

HBPLS01 Inclusion Criteria: 1. Adult individual at least 18 years old 2. Clinical diagnosis Primary Lateral Sclerosis. 3. Subject or Legal Authorized Representative has provided informed consent before initiation of any study procedure. 4. Subject has mesenchymal stem cells banked at Hope Biosciences. Exclusion Criteria: 1. Clinically significant, uncontrolled cardiovascular, lung, renal, hepatic, or endocrine disease or any other acute or chronic medical condition that, in the opinion of the principal investigator, may increase the risks associated with study participation. 2. Chemical or ETOH dependency that in the opinion of the investigator would preclude participation in the study. 3. Participation in concurrent interventional research studies during this expanded access. 4. Unwillingness to return for follow-up visits.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary lateral sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lateral sclerosis motor neuron disorder Papillon-Lefevre disease primary lateral sclerosis, adult, 1 Sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary lateral sclerosis, adult, 1

Contacts and locations

Locations

  • Hope Biosciences Stem Cell Research Foundation

    Sugar Land, Texas, 77478, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.